Exp Clin Endocrinol Diabetes 2022; 130(10): 636-637
DOI: 10.1055/a-1903-1752
Editorial

Advanced Glycation End Products: Do They Impair Bone Health in Diabetes?

Stella Papachristou
1   Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece
,
Manfredi Rizzo
2   Department of Health Promotion Sciences, Maternal and Infantile Care, Internal Medicine and Medical Specialties (Promise), School of Medicine, University of Palermo, Italy
,
Nikolaos Papanas
1   Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece
› Author Affiliations
Preview

Abstract

In diabetes mellitus (DM), there is increased formation and accumulation of advanced glycation end products (AGEs), which represent a heterogeneous class of molecules produced by non-enzymatic glycation of various molecules during long-term hyperglycaemia. Several studies have examined the role of AGEs in DM complications. Accumulating evidence suggests that AGEs affect bone metabolism. New knowledge indicates that they may play a role in bone disease among DM subjects. More data are now needed to clarify their role and to explore new AGEs-based therapeutic options for optimal bone health in DM.



Publication History

Received: 11 June 2022
Received: 29 June 2022

Accepted: 07 July 2022

Article published online:
17 August 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany